Curis, Inc.(CRIS)Earnings, Financials & Key RatiosCuris, Inc. (CRIS) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
with cash reserves of only $15.0M as of 2026Q1 and a history of quarterly operating losses that frequently exceed $10M, signaling an imminent risk of further shareholder dilution.
Curis, Inc. (CRIS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Curis, Inc. (CRIS) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $1.25vs $0.29-331.0% | —vs $2M |
| Q2 2026 | Mar 19, 2026 | $0.50vs $0.44-14.7% | $1Mvs $3M-65.0% |
| Q4 2025 | Nov 6, 2025 | $0.49vs $0.62+21.0% | $3Mvs $3M+11.0% |
| Q3 2025 | Aug 5, 2025 | $0.68vs $1.99+65.8% | $3Mvs $3M-3.9% |
Recent stock market news and headlines for Curis, Inc. (CRIS)
Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Rever
Eleven sites open for patient enrollment in TakeAim CLL combination study with zanubrutinib; Company reaffirms guidance for dosing of initial five patients by end of July 2026 with data expected December 2026; Stockholders approve reverse stock split LEXINGTON, Mass., June 26, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that eleven clinical sites have been initiated and are now open for patient enrollment in its Phase 2 TakeAim CLL study evaluating emavusertib in combination with zanubrutinib in patients with Chronic Lymphocytic Leukemia.
Key metrics vs top competitors for Curis, Inc. (CRIS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.94 | $11.58M | -0.51 | -13.43% | -80.29% | -138.81% | — | |
| $53.52 | $8.19B | 19.32 | 87.32% | 65.95% | 87.36% | — | |
| $9.62 | $82.13M | -0.54 | 0.57% | -129.02% | — | — | |
| $4.57 | $290.48M | -3.87 | 0.78% | -44.79% | -147.8% | — | |
| $38.60 | $7.92B | -13.94 | — | — | -68.16% | — | |
| $9.50 | $497.36M | -2.10 | -92.84% | -260.92% | -49.88% | — |
Curis, Inc. (CRIS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Curis, Inc. (CRIS) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 22, 2026·SEC
May 12, 2026·SEC
May 1, 2026·SEC
Get notified when CRIS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Curis, Inc. (CRIS) stock FAQ — growth, dividends, profitability & financials explained
Curis, Inc. (CRIS) reported $7.1M in revenue for fiscal year 2025. This represents a 120% increase from $3.2M in 1999.
Curis, Inc. (CRIS) saw revenue decline by 13.4% over the past year.
Curis, Inc. (CRIS) reported a net loss of $21.2M for fiscal year 2025.
Curis, Inc. (CRIS) has a return on equity (ROE) of -138.8%. Negative ROE indicates the company is unprofitable.
Curis, Inc. (CRIS) had negative free cash flow of $28.9M in fiscal year 2025, likely due to heavy capital investments.
